...
首页> 外文期刊>JMIR Research Protocols >Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol
【24h】

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol

机译:Web访问人群药代动力学服务的开发-血友病(WAPPS-Hemo):研究方案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Individual pharmacokinetic assessment is a critical component of tailored prophylaxis for hemophilia patients. Population pharmacokinetics allows using individual sparse data, thus simplifying individual pharmacokinetic studies. Implementing population pharmacokinetics capacity for the hemophilia community is beyond individual reach and requires a system effort. Objective The Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo) project aims to assemble a database of patient pharmacokinetic data for all existing factor concentrates, develop and validate population pharmacokinetics models, and integrate these models within a Web-based calculator for individualized pharmacokinetic estimation in patients at participating treatment centers. Methods Individual pharmacokinetic studies on factor VIII and IX concentrates will be sourced from pharmaceutical companies and independent investigators. All factor concentrate manufacturers, hemophilia treatment centers (HTCs), and independent investigators (identified via a systematic review of the literature) having on file pharmacokinetic data and willing to contribute full or sparse pharmacokinetic data will be eligible for participation. Multicompartmental modeling will be performed using a mixed-model approach for derivation and Bayesian forecasting for estimation of individual sparse data. NONMEM (ICON Development Solutions) will be used as modeling software. Results The WAPPS-Hemo research network has been launched and is currently joined by 30 HTCs from across the world. We have gathered dense individual pharmacokinetic data on 878 subjects, including several replicates, on 21 different molecules from 17 different sources. We have collected sparse individual pharmacokinetic data on 289 subjects from the participating centers through the testing phase of the WAPPS-Hemo Web interface. We have developed prototypal population pharmacokinetics models for 11 molecules. The WAPPS-Hemo website (available at www.wapps-hemo.org, version 2.4), with core functionalities allowing hemophilia treaters to obtain individual pharmacokinetic estimates on sparse data points after 1 or more infusions of a factor concentrate, was launched for use within the research network in July 2015. Conclusions The WAPPS-Hemo project and research network aims to make it easier to perform individual pharmacokinetic assessments on a reduced number of plasma samples by adoption of a population pharmacokinetics approach. The project will also gather data to substantially enhance the current knowledge about factor concentrate pharmacokinetics and sources of its variability in target populations. Trial Registration ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT02061072","term_id":"NCT02061072"}} NCT02061072 ; https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT02061072","term_id":"NCT02061072"}} NCT02061072 (Archived by WebCite at http://www.webcitation.org/6mRK9bKP6).
机译:背景个体药代动力学评估是针对血友病患者进行预防性预防的关键组成部分。群体药代动力学可以使用单独的稀疏数据,从而简化了单独的药代动力学研究。实现血友病社区的人群药代动力学能力是个人无法企及的,需要系统的努力。目的可通过网络访问的人群药代动力学服务—血友病(WAPPS-Hemo)项目旨在为所有现有因子浓缩物建立患者药代动力学数据的数据库,开发和验证人群药代动力学模型,并将这些模型整合到基于Web的计算器中以进行个性化参与治疗中心患者的药代动力学估算。方法VIII和IX因子浓缩物的单独药代动力学研究将来自制药公司和独立研究人员。所有具备药代动力学数据并愿意提供完整或稀疏药代动力学数据的浓缩因子制造商,血友病治疗中心(HTC)和独立研究者(通过文献的系统综述确定)将有资格参加。多室建模将使用混合模型方法进行推导,并使用贝叶斯预测进行估计,以估计单个稀疏数据。 NONMEM(ICON开发解决方案)将用作建模软件。结果WAPPS-Hemo研究网络已经启动,目前全球30个HTC加入了该网络。我们收集了来自878位受试者的密集个体药代动力学数据,包括来自17种不同来源的21种不同分子的多次重复。在WAPPS-Hemo Web界面的测试阶段,我们从参与中心收集了289个受试者的稀疏个体药代动力学数据。我们已经开发了11种分子的原型群体药代动力学模型。推出了WAPPS-Hemo网站(可从www.wapps-hemo.org,版本2.4)获得,其核心功能允许血友病治疗者在输注1次或多次浓缩因子后在稀疏数据点上获得单独的药代动力学估计。该研究网络于2015年7月成立。结论WAPPS-Hemo项目和研究网络旨在通过采用群体药代动力学方法,使对数量减少的血浆样品进行单独的药代动力学评估变得更加容易。该项目还将收集数据,以大大增强有关因子浓缩药代动力学及其在目标人群中变异性来源的当前知识。试验注册ClinicalTrials.gov {“ type”:“ clinical-trial”,“ attrs”:{“ text”:“ NCT02061072”,“ term_id”:“ NCT02061072”}} NCT02061072; https://clinicaltrials.gov/ct2/show/ {“ type”:“ clinical-trial”,“ attrs”:{“ text”:“ NCT02061072”,“ term_id”:“ NCT02061072”}} NCT02061072(由WebCite存档在http://www.webcitation.org/6mRK9bKP6)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号